logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Relebactam in combination with imipenem and cilastatin for the treatment of drug resistant Gram-negative infections

< Back

Relebactam in combination with imipenem and cilastatin for the treatment of drug resistant Gram-negative infections

Drugs

Infectious Disease and Immunisation

July 2016


Hospital acquired infections: including hospital acquired pneumonia, ventilator associated pneumonia, complicated urinary tract infections and complicated intra-abdominal infections are serious infections and a huge problem for the NHS. They prolong patients’ stay in hospital and increase health costs. These infections are frequently caused by Gram negative bacteria that are becoming increasingly resistant to commonly prescribed antibiotics and are a serious global concern.If licensed, relebactam in combination with imipenem/cilastatin will offer a treatment option for those patients who have acquired a serious infection caused by multi-drug resistant and carbapenem resistant Gram-negative bacteria.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts